Anjali Rohatgi

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Beyond PD-1: The Next Frontier for Immunotherapy in Melanoma”.

Beyond PD-1: The Next Frontier for Immunotherapy in Melanoma

Frontiers in Oncology(2021)10.3389/fonc.2021.640314

N/A

0DataRank · unranked

17 citations

John M. Kirkwood, Anjali Rohatgi

Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunity

Cell(2024)10.1016/j.cell.2024.06.036

N/A

0DataRank · unranked

157 citations

Carly Cardello, Feng Shan, Lilit Karapetyan, Sheryl Kunning, Cindy Sander +9 more

Lead-in therapy targeting PD1 and/or LAG3 imposes distinct immune phenotypes in first-line treatment of metastatic melanoma

medRxiv(2025)10.1101/2025.11.04.25339499

N/A

0DataRank · unranked

2 citations

Anthony R. Cillo, Shuaichao Wang, Arivarasan Karunamurthy, Ryan Massa, Anjali Rohatgi +16 more

1340 Lead-in therapy targeting PD1 and/or LAG3 distinguishes differential impacts upon the immune response in first-line treatment of metastatic melanoma

(2025)10.1136/jitc-2025-sitc2025.1340

N/A

0DataRank · unranked

0 citations

Anthony R. Cillo, Shuaichao Wang, Arivarasan Karunamurthy, Ryan Massa, Anjali Rohatgi +15 more